Advanced in Virilizing Ovarian Tumor

Dr. Abhinav B. Chandra

Hematology Oncology | Hematology | Oncology
2400 S Ave A, 
Yuma, AZ 
 (1866.5 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Advanced in Virilizing Ovarian Tumor
2400 S Ave A, 
Yuma, AZ 
 (1866.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

Abhinav Chandra is a Hematologist Oncology specialist and a Hematologist in Yuma, Arizona. Dr. Chandra and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Myelodysplastic Syndrome (MDS), and Thrombocytopenia. Dr. Chandra is currently accepting new patients.

His clinical research consists of co-authoring 45 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Yuma Regional Medical Center
Languages Spoken
English
Hindi
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

YUMA REGIONAL MEDICAL CENTER
2400 S Ave A, Yuma, AZ 85364

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: May 17, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Bortezomib, Lenalidomide, Dexamethasone
Study Phase: Phase 1
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy
Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy
Enrollment Status: Recruiting
Publish Date: December 18, 2023
Intervention Type: Biological, Other
Study Drugs: Pertuzumab, Sargramostim, Trastuzumab, Trastuzumab Emtansine, Vaccine Therapy
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab
Enrollment Status: Withdrawn
Publish Date: May 26, 2022
Intervention Type: Drug, Biological
Study Drugs: Abemaciclib, Trastuzumab Emtansine
Study Phase: Phase 2
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

45 Total Publications

A Case of Solitary Amyloid Lung Nodule Treated With Surgery.
A Case of Solitary Amyloid Lung Nodule Treated With Surgery.
Journal: Cureus
Published: August 16, 2024
Similar Doctors
Experienced in Virilizing Ovarian Tumor
Dr. Syed H. Ahmed
Hematology Oncology | Hematology | Oncology
Experienced in Virilizing Ovarian Tumor
Dr. Syed H. Ahmed
Hematology Oncology | Hematology | Oncology

S H Ahmed MD Phd Inc

1271 Ross Ave, 
El Centro, CA 
 (53.1 mi)
760-335-3030
Languages Spoken:
English
Offers Telehealth

Syed Ahmed is a Hematologist Oncology specialist and a Hematologist in El Centro, California. Dr. Ahmed and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Breast Cancer, and Paget Disease of the Breast.

Experienced in Virilizing Ovarian Tumor
Dr. Augustine W. Lau
Hematology Oncology | Aerospace Medicine | Hematology
Experienced in Virilizing Ovarian Tumor
Dr. Augustine W. Lau
Hematology Oncology | Aerospace Medicine | Hematology
2375 S. Ridgeview Drive, 
Yuma, AZ 
 (1.7 mi)
928-317-2518
Experience:
21+ years
Languages Spoken:
English

Augustine Lau is a Hematologist Oncology specialist and an Aerospace Medicine provider in Yuma, Arizona. Dr. Lau has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Agranulocytosis, Chronic Familial Neutropenia, Familial Colorectal Cancer, and WT1-Related Wilms Tumor Syndromes.

Experienced in Virilizing Ovarian Tumor
Dr. Saqib Razzaque
Hematology Oncology | Hematology | Oncology
Experienced in Virilizing Ovarian Tumor
Dr. Saqib Razzaque
Hematology Oncology | Hematology | Oncology

S H Ahmed MD Phd Inc

1271 Ross Ave, 
El Centro, CA 
 (53.1 mi)
760-335-3030
Languages Spoken:
English
Offers Telehealth

Saqib Razzaque is a Hematologist Oncology specialist and a Hematologist in El Centro, California. Dr. Razzaque and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Hairy Cell Leukemia (HCL), Inflammatory Breast Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile